Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes that their parent/guardian can and will comply with the requirements of the protocol should be enrolled in the study.~* A male or female between, and including, 6 and 12 weeks of age at the time of the first vaccination.~* Born after a gestation period of 36 to 42 weeks inclusive.~* Healthy subjects as established by medical history before entering into the study.~* Written informed consent obtained from the parent or guardian of the subject.~Exclusion Criteria:~* Use of any investigational or non-registered product within 30 days preceding the first dose of study vaccine, or planned use during the study period.~* Chronic administration of immunosuppressants or other immune-modifying drugs from birth until first primary vaccination dose..~* Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.~* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.~* Major congenital defects or serious chronic illness.~* Evidence of previous or intercurrent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B and/or Hib vaccination or disease.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history.~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccines.~* The following condition is temporary or self limiting and a subject may be vaccinated once the condition has resolved and no other exclusion criteria are met:~* Current febrile illness or axillary temperature of ≥ 37.5 ºC or other moderate to severe illness within 24 hours of study vaccine administration.

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 12 Weeks
- Healthy Volunteers: t

Study Arms:
- Aboriginal infants group (Type: EXPERIMENTAL): None
- Other Non-Aboriginal infants (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).